David Lamond Biography and Net Worth

Director of Cortexyme

David A. Lamond joined our board of directors in 2015. Since April 2016, Mr. Lamond has served as president of En Pointe LLC, an investment firm. From 2011 to 2016, he served as the president, chief executive officer and chief investment officer of Lamond Capital Partners LLC. Mr. Lamond also is currently a member of the board of directors of Applied Molecular Transport (AMTI), a biopharmaceutical company, and previously served on the board of Arrinex, a medical device company. In addition, Mr. Lamond is on the board of directors of two non-profit organizations, Tipping Point Community and Ubuntu Pathways. Mr. Lamond holds a B.A. in History from Duke University and a J.D. from Duke Law School.

What is David Lamond's net worth?: The estimated net worth of David Lamond is at least $4.79 million as of December 12th, 2023. Mr. Lamond owns 2,302,291 shares of Cortexyme stock worth more than $4,788,765 as of November 21st. This net worth approximation does not reflect any other investments that Mr. Lamond may own. Learn More about David Lamond's net worth.
How do I contact David Lamond?: The corporate mailing address for Mr. Lamond and other Cortexyme executives is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. Cortexyme can also be reached via phone at (650) 910-5717 and via email at [email protected]. Learn More on David Lamond's contact information.
Has David Lamond been buying or selling shares of Cortexyme?: David Lamond has not been actively trading shares of Cortexyme during the past quarter. Most recently, on Wednesday, March 24th, David Lamond bought 50,000 shares of Cortexyme stock. The stock was acquired at an average cost of $33.77 per share, with a total value of $1,688,500.00. Following the completion of the transaction, the director now directly owns 301,829 shares of the company's stock, valued at $10,192,765.33. Learn More on David Lamond's trading history.
Who are Cortexyme's active insiders?: Cortexyme's insider roster includes Michael Detke (Insider), Stephen Dominy (Insider), David Lamond (Director), Christopher Lowe (CFO), Casey Lynch (CEO), and Margaret Mcloughlin (Director). Learn More on Cortexyme's active insiders.

David Lamond Insider Trading History at Cortexyme

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/24/2021	Buy	50,000	$33.77	$1,688,500.00	301,829
6/4/2020	Buy	49,125	$41.73	$2,049,986.25	301,829
5/19/2020	Buy	44,648	$56.09	$2,504,306.32	301,829
5/15/2020	Buy	5,448	$48.93	$266,570.64	301,829

David Lamond Buying and Selling Activity at Cortexyme

Cortexyme Company Overview

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Today's Range

Now: $2.08

$1.80

$2.14

50 Day Range

MA: $1.07

$0.69

$1.95

2 Week Range

Now: $2.08

$1.78

$40.66

Volume

312,412 shs

Average Volume

620,672 shs

Market Capitalization

$62.71 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4

“This Changes Everything” - Trump Hands Millions Massive IRS Gift

From Colonial Metals | Ad

Now it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…

>> YES! Send Me My FREE Gold Guide!